Phosphodiesterase 4 inhibitor combined with secukinumab relieves clinical symptoms in patients with psoriasis via regulating p38MAPK activation and the immune response inflammation.

BACKGROUND

The purpose of the present study was to explore the effect of phosphodiesterase 4 (PDE-4) inhibitor combined with secukinumab monoclonal antibody on the activation level of p38 mitogen-activated protein kinases (p38MAPK) in psoriatic leukocytes.

METHODOLOGY: The clinical data of 60 patients with psoriasis were retrospectively analyzed, and they were divided into a control group (secukinumab monotherapy, 30 cases) and a study group (PDE-4 inhibitory therapy). Agent combined with secukinumab treatment(30 cases), all were treated for 3 months. The Psoriasis Area and Severity Index (PASI), clinical symptom score, serum inflammatory factors, p38MAPK gene expression in lesion tissue, and clinical outcome were compared between the two groups.

RESULTS

After treatment, the PSAI score (t=5.051) and symptom score (t=14.102) of the study group were lower than those of the control group, and the relative expression of interleukin-6 (IL-6) (t=7.514) and p38MAPK (t=4.219), the relative expression of interleukin-17 (IL-17) (t=2.579) was lower than that of the control group. The total effective rate in the study group (83.33% vs. 60.00%) was higher than that in the control group.

CONCLUSION

Secukinumab along with phosphodiesterase 4 inhibitors reduces p38MAPK activation, and improves immune response, inflammation, and clinical symptoms in patients with psoriasis.